Quantedge Capital’s Regenxbio RGNX Stock Holding History

Quantedge Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,400	Closed	-$592K	–	209
2022 Q3	$592K	Sell	22,400 -20,300	-48%	-$602K	0.18%	115
2022 Q2	$1.05M	Buy	+42,700	New	+$1.07M	0.21%	122

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Quantedge Capital's RGNX Position: Q4 2022 in Review

Quantedge Capital sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 22,400 shares — an estimated $592K sold.

Quantedge Capital first reported a position in RGNX in Q2 2022 and held it in 2 quarters. The position peaked at $1.05M in Q2 2022. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

Quantedge Capital reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
Quantedge Capital sold 22,400 Regenxbio shares in Q4 2022, an estimated $592K.
Quantedge Capital first reported a position in Regenxbio in Q2 2022 and held it in 2 quarters.
Quantedge Capital's Regenxbio position peaked at $1.05M in Q2 2022.
180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Quantedge Capital's 13F filing for Q4 2022, filed 14 Feb 2023.